Literature DB >> 19850741

MicroRNA 29b functions in acute myeloid leukemia.

Ramiro Garzon1, Catherine E A Heaphy, Violaine Havelange, Muller Fabbri, Stefano Volinia, Twee Tsao, Nicola Zanesi, Steven M Kornblau, Guido Marcucci, George A Calin, Michael Andreeff, Carlo M Croce.   

Abstract

MicroRNAs (miRNAs) are associated with cytogenetics and molecular subtypes of acute myelogeneous leukemia (AML), but their impact on AML pathogenesis is poorly understood. We have previously shown that miR-29b expression is deregulated in primary AML blasts. In this work, we investigated the functional role of miR-29b in leukemogenesis. Restoration of miR-29b in AML cell lines and primary samples induces apoptosis and dramatically reduces tumorigenicity in a xenograft leukemia model. Transcriptome analysis after ectopic transfection of synthetic miR-29b into leukemia cells indicates that miR-29b target apoptosis, cell cycle, and proliferation pathways. A significant enrichment for apoptosis genes, including MCL-1, was found among the mRNAs inversely correlated with miR-29b expression in 45 primary AML samples. Together, the data support a tumor suppressor role for miR-29 and provide a rationale for the use of synthetic miR-29b oligonucleotides as a novel strategy to improve treatment response in AML.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19850741      PMCID: PMC2796138          DOI: 10.1182/blood-2009-03-211938

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  38 in total

Review 1.  BH3-Only proteins-essential initiators of apoptotic cell death.

Authors:  D C Huang; A Strasser
Journal:  Cell       Date:  2000-12-08       Impact factor: 41.582

2.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

3.  TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23).

Authors:  R B Lorsbach; J Moore; S Mathew; S C Raimondi; S T Mukatira; J R Downing
Journal:  Leukemia       Date:  2003-03       Impact factor: 11.528

4.  An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans.

Authors:  N C Lau; L P Lim; E G Weinstein; D P Bartel
Journal:  Science       Date:  2001-10-26       Impact factor: 47.728

5.  MiR-15a and miR-16-1 cluster functions in human leukemia.

Authors:  George A Calin; Amelia Cimmino; Muller Fabbri; Manuela Ferracin; Sylwia E Wojcik; Masayoshi Shimizu; Cristian Taccioli; Nicola Zanesi; Ramiro Garzon; Rami I Aqeilan; Hansjuerg Alder; Stefano Volinia; Laura Rassenti; Xiuping Liu; Chang-Gong Liu; Thomas J Kipps; Massimo Negrini; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-24       Impact factor: 11.205

6.  MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia.

Authors:  Mojca Jongen-Lavrencic; Su Ming Sun; Menno K Dijkstra; Peter J M Valk; Bob Löwenberg
Journal:  Blood       Date:  2008-03-12       Impact factor: 22.113

7.  Functional proteomic profiling of AML predicts response and survival.

Authors:  Steven M Kornblau; Raoul Tibes; Yi Hua Qiu; Wenjing Chen; Hagop M Kantarjian; Michael Andreeff; Kevin R Coombes; Gordon B Mills
Journal:  Blood       Date:  2008-10-07       Impact factor: 22.113

8.  NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma.

Authors:  Huating Wang; Ramiro Garzon; Hao Sun; Katherine J Ladner; Ravi Singh; Jason Dahlman; Alfred Cheng; Brett M Hall; Stephen J Qualman; Dawn S Chandler; Carlo M Croce; Denis C Guttridge
Journal:  Cancer Cell       Date:  2008-11-04       Impact factor: 31.743

9.  Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin.

Authors:  Ramiro Garzon; Michela Garofalo; Maria Paola Martelli; Roger Briesewitz; Lisheng Wang; Cecilia Fernandez-Cymering; Stefano Volinia; Chang-Gong Liu; Susanne Schnittger; Torsten Haferlach; Arcangelo Liso; Daniela Diverio; Marco Mancini; Giovanna Meloni; Robin Foa; Massimo F Martelli; Cristina Mecucci; Carlo M Croce; Brunangelo Falini
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-28       Impact factor: 11.205

10.  Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis.

Authors:  Eva van Rooij; Lillian B Sutherland; Jeffrey E Thatcher; J Michael DiMaio; R Haris Naseem; William S Marshall; Joseph A Hill; Eric N Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-22       Impact factor: 11.205

View more
  204 in total

1.  Epigenetic changes mediated by microRNA miR29 activate cyclooxygenase 2 and lambda-1 interferon production during viral infection.

Authors:  Jiali Fang; Qian Hao; Li Liu; Yongkui Li; Jianguo Wu; Xixiang Huo; Ying Zhu
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

Review 2.  The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury.

Authors:  Alison J Kriegel; Yong Liu; Yi Fang; Xiaoqiang Ding; Mingyu Liang
Journal:  Physiol Genomics       Date:  2012-01-03       Impact factor: 3.107

3.  Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors.

Authors:  Gregory J Gores; Scott H Kaufmann
Journal:  Genes Dev       Date:  2012-02-15       Impact factor: 11.361

Review 4.  Causes and consequences of microRNA dysregulation.

Authors:  Marilena V Iorio; Carlo M Croce
Journal:  Cancer J       Date:  2012 May-Jun       Impact factor: 3.360

5.  miR-29ab1 deficiency identifies a negative feedback loop controlling Th1 bias that is dysregulated in multiple sclerosis.

Authors:  Kristen M Smith; Mireia Guerau-de-Arellano; Stefan Costinean; Jessica L Williams; Arianna Bottoni; Gina Mavrikis Cox; Abhay R Satoskar; Carlo M Croce; Michael K Racke; Amy E Lovett-Racke; Caroline C Whitacre
Journal:  J Immunol       Date:  2012-07-06       Impact factor: 5.422

Review 6.  Strategies to Modulate MicroRNA Functions for the Treatment of Cancer or Organ Injury.

Authors:  Tae Jin Lee; Xiaoyi Yuan; Keith Kerr; Ji Young Yoo; Dong H Kim; Balveen Kaur; Holger K Eltzschig
Journal:  Pharmacol Rev       Date:  2020-07       Impact factor: 25.468

Review 7.  Clinical significance of the interaction between non-coding RNAs and the epigenetics machinery: challenges and opportunities in oncology.

Authors:  Beatriz M Maia; Rafael M Rocha; George A Calin
Journal:  Epigenetics       Date:  2013-10-11       Impact factor: 4.528

Review 8.  The therapeutic potential of microRNAs: disease modulators and drug targets.

Authors:  Ailbhe M McDermott; Helen M Heneghan; Nicola Miller; Michael J Kerin
Journal:  Pharm Res       Date:  2011-08-05       Impact factor: 4.200

9.  Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia.

Authors:  Xiaomeng Huang; Sebastian Schwind; Bo Yu; Ramasamy Santhanam; Hongyan Wang; Pia Hoellerbauer; Alice Mims; Rebecca Klisovic; Alison R Walker; Kenneth K Chan; William Blum; Danilo Perrotti; John C Byrd; Clara D Bloomfield; Michael A Caligiuri; Robert J Lee; Ramiro Garzon; Natarajan Muthusamy; Ly James Lee; Guido Marcucci
Journal:  Clin Cancer Res       Date:  2013-03-14       Impact factor: 12.531

Review 10.  Cell-to-cell miRNA transfer: from body homeostasis to therapy.

Authors:  Roxana S Redis; Steliana Calin; Yaling Yang; M James You; George A Calin
Journal:  Pharmacol Ther       Date:  2012-08-08       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.